ACAD Live signals | Maximize Profits with Getagraph.com

SELL 102914 min ago

@ $25.78

Issued: 14 Feb 2024 @ 15:32

Return: -36.73%

Previous signal: Feb 14 - 13:10

Previous signal: Buy

Return: 0.72 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	1.63M
Average Volume	1.79M
Market Cap	2.69B
EPS	$0 ( 2024-02-27 )
Next earnings date	( $0.180 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-44.08
ATR14	$0.0130 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-04	Thompson Elizabeth H.z.	Buy	0
2024-04-05	Davis Stephen	Buy	34 666	Common Stock
2024-04-08	Davis Stephen	Sell	8 858	Common Stock
2024-04-08	Davis Stephen	Sell	17 716	Common Stock
2024-04-05	Davis Stephen	Sell	34 666	Restricted Stock Units

INSIDER POWER
31.75
Last 98 transactions
Buy: 1 174 699 \| Sell: 709 800

Volume Correlation

Long: 0.02 (neutral)

Short: 0.74 (moderate)

Signal:(52.018) Neutral

ACADIA Pharmaceuticals Correlation

10 Most Positive Correlations
BIOL	0.951
SONN	0.938
BGXX	0.936
AKTS	0.935
WB	0.935
HCM	0.934
ALLR	0.933
COKE	0.931
PROG	0.931
PHUN	0.93

10 Most Negative Correlations
TUEM	-0.954
LCA	-0.936
USCB	-0.933
MCAA	-0.929
MSDA	-0.928
FXCO	-0.926
PRSR	-0.926
MSDAU	-0.925
ACBA	-0.923
BRIVU	-0.923

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ACADIA Pharmaceuticals Correlation - Currency/Commodity

0.43
( neutral )

0.23
( neutral )

0.00
( neutral )

0.07
( neutral )

-0.45
( neutral )

-0.39
( neutral )

ACADIA Pharmaceuticals Financials

Annual	2023
Revenue:	$726.44M
Gross Profit:	$680.71M (93.70 %)
EPS:	$-0.370

FY	2023
Revenue:	$726.44M
Gross Profit:	$680.71M (93.70 %)
EPS:	$-0.370

FY	2022
Revenue:	$517.24M
Gross Profit:	$507.07M (98.03 %)
EPS:	$-1.340

FY	2021
Revenue:	$484.15M
Gross Profit:	$465.00M (96.05 %)
EPS:	$-1.067

Financial Reports:

No articles found.

ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.